Drug Trial Radar · NCT05633615
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
396
Planned (sponsor's estimate)
Start
Jun 12, 2023
Primary completion
Jun 30, 2030
Study completion Jun 30, 2030
Sponsor
- Lead sponsor
- SWOG Cancer Research NetworkResearch network
- Sponsor type
- Research network
- Collaborators
- National Cancer Institute (NCI); Genentech, Inc.
- First posted
- Dec 1, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase II trial tests whether mosunetuzumab and/or polatuzumab vedotin helps benefit patients who have received chemotherapy (fludarabine and cyclophosphamide) followed by chimeric antigen receptor (CAR) T-cell therapy (tisagenlecleucel, axicabtagene ciloleucel, or lisocabtagene maraleucel) for diffuse large B-cell lymphoma that has come back (recurrent) or that does not respond to treatment (refractory) or grade IIIb follicular lymphoma. Mosunetuzumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Polatuzumab vedotin is a monoclonal antibody, called polatuzumab, linked to a drug called vedotin. Polatuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, and delivers vedotin to kill them. Chemotherapy drugs, such as fludarabine and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. CAR T-cell therapy is a type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells. T cells are taken from a patient's blood. Then the gene for a special receptor that binds to a certain protein on the patient's cancer cells is added to the T cells in the laboratory. The special receptor is called a chimeric antigen receptor. Large numbers of the CAR T cells are grown in the laboratory and given to the patient by infusion for treatment of certain cancers. Giving mosunetuzumab and/or polatuzumab vedotin after chemotherapy and CAR T-cell therapy may be more effective at controlling or shrinking the cancer than not giving them.
Conditions
- Diffuse Large B-Cell Lymphoma
- Grade 3b Follicular Lymphoma
- Primary Mediastinal (Thymic) Large B-Cell Lymphoma
- Recurrent Diffuse Large B-Cell Lymphoma
- Refractory Diffuse Large B-Cell Lymphoma
- Transformed Follic Lymph to Diff Large B-Cell Lymphoma
- Transformed Marg Zone Lymph to Diff Large B-Cell Lymphoma
Interventions
Axicabtagene CiloleucelBiological
Given IV
Biospecimen CollectionProcedure
Undergo collection of blood and tissue samples
Computed TomographyProcedure
Undergo PET-CT or CT
CyclophosphamideDrug
Given IV
FludarabineDrug
Given IV
Lisocabtagene MaraleucelBiological
Given IV
MosunetuzumabBiological
Given IV
Patient ObservationOther
Undergo observation
Polatuzumab VedotinDrug
Given IV
Positron Emission TomographyProcedure
Undergo PET-CT
TisagenlecleucelBiological
Given IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression free survival (PFS)Time frame: From date of randomization to date of first observation of progressive disease or death due to any cause, assessed up to 2 years
Locations
95 sites in 1 country. Site status is shown where the registry gives one.
Banner University Medical Center - Tucson
Tucson, Arizona · Recruiting
University of Arizona Cancer Center-North Campus
Tucson, Arizona · Recruiting
Highlands Oncology Group - Fayetteville
Fayetteville, Arkansas · Recruiting
University of Arkansas for Medical Sciences
Little Rock, Arkansas · Recruiting
Highlands Oncology Group - Rogers
Rogers, Arkansas · Recruiting
Highlands Oncology Group
Springdale, Arkansas · Recruiting
UC Irvine Health Cancer Center-Newport
Costa Mesa, California · Recruiting
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
Irvine, California · Recruiting
UCI Health Laguna Hills
Laguna Hills, California · Recruiting
UC Irvine Health/Chao Family Comprehensive Cancer Center
Orange, California · Recruiting
UCSF Medical Center-Parnassus
San Francisco, California · Recruiting
UF Health Cancer Institute - Gainesville
Gainesville, Florida · Recruiting
Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia · Recruiting
Emory Saint Joseph's Hospital
Atlanta, Georgia · Recruiting
Saint Luke's Cancer Institute - Boise
Boise, Idaho · Recruiting
Saint Luke's Cancer Institute - Fruitland
Fruitland, Idaho · Recruiting
Saint Luke's Cancer Institute - Meridian
Meridian, Idaho · Recruiting
Saint Luke's Cancer Institute - Nampa
Nampa, Idaho · Recruiting
Saint Luke's Cancer Institute - Twin Falls
Twin Falls, Idaho · Recruiting
University of Illinois
Chicago, Illinois · Recruiting
University of Chicago Comprehensive Cancer Center
Chicago, Illinois · Recruiting
Loyola University Medical Center
Maywood, Illinois · Recruiting
University of Iowa/Holden Comprehensive Cancer Center
Iowa City, Iowa · Recruiting
University of Kansas Cancer Center
Kansas City, Kansas · Recruiting
University of Kansas Cancer Center-Overland Park
Overland Park, Kansas · Recruiting
University of Kansas Hospital-Westwood Cancer Center
Westwood, Kansas · Recruiting
The James Graham Brown Cancer Center at University of Louisville
Louisville, Kentucky · Recruiting
UofL Health Medical Center Northeast
Louisville, Kentucky · Recruiting
LSU Health Baton Rouge-North Clinic
Baton Rouge, Louisiana · Recruiting
Our Lady of the Lake Physician Group
Baton Rouge, Louisiana · Recruiting
University of Maryland/Greenebaum Cancer Center
Baltimore, Maryland · Recruiting
Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore, Maryland · Recruiting
Bronson Battle Creek
Battle Creek, Michigan · Recruiting
Henry Ford Macomb Hospital-Clinton Township
Clinton Township, Michigan · Recruiting
Henry Ford Medical Center-Fairlane
Dearborn, Michigan · Recruiting
Wayne State University/Karmanos Cancer Institute
Detroit, Michigan · Recruiting
Henry Ford Hospital
Detroit, Michigan · Recruiting
Weisberg Cancer Treatment Center
Farmington Hills, Michigan · Recruiting
Corewell Health Grand Rapids Hospitals - Butterworth Hospital
Grand Rapids, Michigan · Recruiting
Trinity Health Grand Rapids Hospital
Grand Rapids, Michigan · Suspended
Showing 40 of 95 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.